Black Diamond Therapeutics closed at $1.90 on Nov 4, up 4.97%, 61.0% below its 52-week closing high. Volume of 607.8K shares was 0.70× its 20-day average (below normal).
Split-adjusted performance: +5.6% over one month, -32.6% over six months, -51.9% over one year.
Short interest was 5.0M shares at the Oct 15 settlement, up 4.8% from the prior report (11.8% of float, 7.3 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BDTXBlack Diamond Therapeutics | $1.90 | +4.97% | −32.6% | — | — | — | $109.2M | |
| LENZLENZ Therapeutics | $3.46 | −1.14% | −64.3% | +9.7% | −581.8% | — | $108.7M | Compare |
| NMRANeumora Therapeutics | $0.5660 | −0.86% | −75.7% | — | — | — | $106.3M | Compare |
| OTLKOutlook Therapeutics | $0.4621 | +0.46% | +99.4% | −99.4% | −233554.9% | — | $112.5M | Compare |
| VYGRVoyager Therapeutics | $1.87 | +2.19% | −55.2% | −39.1% | −773.2% | — | $115.2M | Compare |
| ENGNenGene Therapeutics | $1.72 | +6.17% | −80.6% | — | — | — | $115.3M | Compare |
| ARMPArmata Pharmaceuticals | $3.14 | +1.62% | −65.3% | +15.7% | 2953.8% | — | $116.8M | Compare |
| AVXLAnavex Life Sciences | $1.26 | +5.00% | −62.3% | — | — | — | $116.8M | Compare |
| HUMAHumacyte | $0.4500 | +2.16% | −54.2% | +34.9% | −9064.5% | — | $125.0M | Compare |
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
